The mission of the Cell Manipulation Core Facility is to produce safe and effective cellular components for patients enrolled in novel therapeutic clinical research protocols. In this context, the Core supports primarily translational research and works closely with many laboratory investigators in the Cancer Immunology Program as well as with clinical investigators in disease-focused Programs within DF/HCC. These Cancer Center investigators work in diverse areas including hematopoietic stem cell transplantation, cancer vaccines and adoptive cellular therapy of cancer. All procedures are performed according to current Good Manufacturing Practices (cGMPs) for cell and tissue processing. Regulations and standards have been developed by the FDA's Center for Biologies Evaluation and Research (CBER), the American Association of Blood Banks (AABB), and the Foundation for the Accreditation of Cellular Therapy (FACT). The policies and procedures established in the facility comply with these standards and regulations, ensuring the production of safe, effective components for clinical use. Cellular products processed by the Core are provided in the context of clinical research protocols that have been reviewed and approved by the Cancer Center Scientific Review Committee and Institutional Review Board. Together with adherence to cGMPs, the requirement that extensive cell processing is only provided for patients enrolled on approved clinical research protocols ensures that this core facility provides a unique service to Cancer Center Research Programs and Members. Director: Jerome Ritz, MD (DFCI) Category: 4.08 (Cell Manufacturing) Management: Joint (Cancer Center and Institutional)

Public Health Relevance

The Cell Manipulation Core Facility produces safe and effective cellular components for patients enrolled in novel therapeutic clinical research protocols. In this context, the Core supports primarily translational research and works closely with many laboratory investigators in the Cancer Immunology Program as well as with clinical investigators in Clinical Programs within DF/HCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-50
Application #
8790976
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2015-11-30
Budget Start
2014-12-01
Budget End
2015-11-30
Support Year
50
Fiscal Year
2015
Total Cost
$293,262
Indirect Cost
$62,960
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945
Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37:
Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534
Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583
Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404
Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917
Kwee, Brian J; Budina, Erica; Najibi, Alexander J et al. (2018) CD4 T-cells regulate angiogenesis and myogenesis. Biomaterials 178:109-121
Madsen, Thomas; Braun, Danielle; Peng, Gang et al. (2018) Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol 42:528-538
Chen, Jingjing; Guccini, Ilaria; Di Mitri, Diletta et al. (2018) Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet 50:219-228
Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609

Showing the most recent 10 out of 411 publications